Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 10/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22367190 | 0.87 | CACNA2D1 (0.41) | RIPK1CACNA2D1SLC6A2NPC1MAOB | |
| SCHEMBL20917472 | 0.87 | CACNA2D1 (0.41) | RIPK1CACNA2D1SLC6A2NPC1MAOB | |
| SCHEMBL21747667 | 0.84 | RIPK1 (0.40) | RIPK1CACNA2D1CTSBCTSSCTSK | |
| SCHEMBL19564591 | 0.84 | RIPK1 (0.40) | RIPK1CACNA2D1CTSBCTSSCTSK | |
| SCHEMBL29457634 | 0.77 | GBA1 (0.45) | RIPK1GBA1CTSSCTSKNPC1 | |
| SCHEMBL20309012 | 0.77 | GBA1 (0.45) | RIPK1GBA1CTSSCTSKNPC1 | |
| SCHEMBL29967173 | 0.77 | GBA1 (0.45) | RIPK1GBA1CTSSCTSKNPC1 | |
| SCHEMBL29967303 | 0.77 | CACNA2D1 (0.69) | CACNA2D1SLC6A2 | |
| SCHEMBL21102740 | 0.77 | CACNA2D1 (0.42) | CACNA2D1SLC6A2GBA1HTR2CSLC6A4 | |
| SCHEMBL19564629 | 0.77 | GBA1 (0.39) | CACNA2D1SLC6A2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | CACNA1B, CACNA1G, CACNA2D2 | RIPK1 4860/4885CACNA2D1 9/4885SLC6A2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.